Skip to main content
. 2020 May 2;9(5):93. doi: 10.3390/biology9050093

Figure 1.

Figure 1

Treatment with Enhancer of Zeste Homolog 2 (EZH2) inhibitors reduces liver steatosis in STAM NASH mice. (A) NASH STAM mice experimental design. STAM-Vehicle (Control) were injected with streptozotocin (STZ) on day 2 to induce a diabetic state. Mice were fed a high-fat diet from four weeks. Mice were dosed with either vehicle, Obeticholic acid, UNC1999, or EPZ6438 once a day from 6–9 weeks for the study. (B) Representative hematoxylin and eosin (H&E) stained (200x) liver sections from healthy (Normal), STAM-Vehicle (Control), STAM-Obeticholic acid (Obeticholic acid), STAM-UNC1999 (UNC1999), and STAM-EZH2 (EPZ6438) groups in the NASH mice. (C) Representative Oil Red O stained (200x) liver sections from healthy (Normal), STAM-Vehicle (Control), STAM-Obeticholic acid (Obeticholic acid), STAM-UNC1999 (UNC1999), and STAM-EZH2 (EPZ6438) groups in the NASH mice. Healthy (Normal), n = 5; Vehicle (Control), n = 5; STAM-Obeticholic acid (Obeticholic acid), n = 5; STAM-UNC1999 (UNC1999) n = 5; STAM-EZH2 (EPZ6438), n = 5.